126 related articles for article (PubMed ID: 26707189)
61. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.
Chun J; Li RJ; Cheng MS; Kim YS
Cancer Lett; 2015 Feb; 357(1):393-403. PubMed ID: 25434800
[TBL] [Abstract][Full Text] [Related]
62. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
63. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
[TBL] [Abstract][Full Text] [Related]
64. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
65. Docosahexaenoic acid suppresses migration of triple-negative breast cancer cell through targeting metastasis-related genes and microRNA under normoxic and hypoxic conditions.
Javadian M; Shekari N; Soltani-Zangbar MS; Mohammadi A; Mansoori B; Maralbashi S; Shanehbandi D; Baradaran B; Darabi M; Kazemi T
J Cell Biochem; 2020 Mar; 121(3):2416-2427. PubMed ID: 31713924
[TBL] [Abstract][Full Text] [Related]
66. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
67. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.
Yang H; Ren L; Wang Y; Bi X; Li X; Wen M; Zhang Q; Yang Y; Jia Y; Li Y; Zang A; Wei Y; Dai G
Cell Death Dis; 2020 Oct; 11(10):851. PubMed ID: 33051436
[TBL] [Abstract][Full Text] [Related]
68. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
69. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
70. Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells.
Hong Y; Fan D
Toxicology; 2019 Apr; 418():22-31. PubMed ID: 30797898
[TBL] [Abstract][Full Text] [Related]
71. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte.
Liu Z; Gan L; Zhou Z; Jin W; Sun C
Immunobiology; 2015 Aug; 220(8):947-53. PubMed ID: 25720636
[TBL] [Abstract][Full Text] [Related]
72. MiR-155 regulates the proliferation and apoptosis of pancreatic cancer cells through targeting SOCS3.
Wang J; Guo J; Fan H
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5168-5175. PubMed ID: 31298410
[TBL] [Abstract][Full Text] [Related]
73. High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission.
Xu AT; Li Y; Zhao D; Shen J; Xu XT; Qiao YQ; Zhu MM; Wang TR; Cui Y; Ai LY; Ran ZH
Inflamm Bowel Dis; 2015 Feb; 21(2):241-50. PubMed ID: 25545374
[TBL] [Abstract][Full Text] [Related]
74. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
[TBL] [Abstract][Full Text] [Related]
75. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
76. STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells.
Liao XH; Xiang Y; Yu CX; Li JP; Li H; Nie Q; Hu P; Zhou J; Zhang TC
Oncotarget; 2017 Feb; 8(9):15763-15774. PubMed ID: 28178652
[TBL] [Abstract][Full Text] [Related]
77. MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3.
Zhong L; Sun S; Shi J; Cao F; Han X; Chen Z
Tumour Biol; 2017 Jun; 39(6):1010428317697579. PubMed ID: 28631574
[TBL] [Abstract][Full Text] [Related]
78. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma.
Cui Q; Jiang W; Wang Y; Lv C; Luo J; Zhang W; Lin F; Yin Y; Cai R; Wei P; Qian C
Hepatology; 2008 Jan; 47(1):105-12. PubMed ID: 17935223
[TBL] [Abstract][Full Text] [Related]
79. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
80. JAK2, STAT3 and SOCS3 gene expression in women with and without breast cancer.
Santillán-Benítez JG; Mendieta-Zerón H; Gómez-Oliván LM; Ordóñez Quiroz A; Torres-Juárez JJ; González-Bañales JM
Gene; 2014 Aug; 547(1):70-6. PubMed ID: 24932998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
